Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more
Sinphar Pharmaceutical Co Ltd (1734) - Net Assets
Latest net assets as of September 2025: NT$3.57 Billion TWD
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has net assets worth NT$3.57 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.13 Billion) and total liabilities (NT$2.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.57 Billion |
| % of Total Assets | 58.33% |
| Annual Growth Rate | 6.57% |
| 5-Year Change | 12.8% |
| 10-Year Change | -10.46% |
| Growth Volatility | 12.36 |
Sinphar Pharmaceutical Co Ltd - Net Assets Trend (2002–2024)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinphar Pharmaceutical Co Ltd (2002–2024)
The table below shows the annual net assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.55 Billion | +4.36% |
| 2023-12-31 | NT$3.40 Billion | +5.63% |
| 2022-12-31 | NT$3.22 Billion | +4.54% |
| 2021-12-31 | NT$3.08 Billion | -2.12% |
| 2020-12-31 | NT$3.14 Billion | -1.84% |
| 2019-12-31 | NT$3.20 Billion | -6.43% |
| 2018-12-31 | NT$3.42 Billion | -5.62% |
| 2017-12-31 | NT$3.63 Billion | -4.11% |
| 2016-12-31 | NT$3.78 Billion | -4.50% |
| 2015-12-31 | NT$3.96 Billion | -2.90% |
| 2014-12-31 | NT$4.08 Billion | +16.73% |
| 2013-12-31 | NT$3.49 Billion | +29.86% |
| 2012-12-31 | NT$2.69 Billion | +1.13% |
| 2011-12-31 | NT$2.66 Billion | +23.13% |
| 2010-12-31 | NT$2.16 Billion | +3.22% |
| 2009-12-31 | NT$2.09 Billion | +17.95% |
| 2008-12-31 | NT$1.77 Billion | +4.41% |
| 2007-12-31 | NT$1.70 Billion | +2.17% |
| 2006-12-31 | NT$1.66 Billion | +1.18% |
| 2005-12-31 | NT$1.64 Billion | +24.92% |
| 2004-12-31 | NT$1.32 Billion | +39.60% |
| 2003-12-31 | NT$942.90 Million | +7.72% |
| 2002-12-31 | NT$875.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinphar Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 291.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$331.30 Million | 10.15% |
| Common Stock | NT$1.81 Billion | 55.51% |
| Other Components | NT$1.12 Billion | 34.34% |
| Total Equity | NT$3.26 Billion | 100.00% |
Sinphar Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern & Oriental Bhd
KLSE:3417
|
$129.70 Million |
|
Grupo Hotelero Santa Fe SAB
MX:HOTEL
|
$129.75 Million |
|
Altia Oyj
F:28Q
|
$129.75 Million |
|
AQUILA PART PROD COM
RO:AQ
|
$129.75 Million |
|
Track & Field Co S.A
SA:TFCO4
|
$129.69 Million |
|
Cyient DLM Limited
NSE:CYIENTDLM
|
$129.69 Million |
|
Gongwin Biopharm Holdings Co. Ltd.
TWO:6617
|
$129.68 Million |
|
Jeju Air Co Ltd
KO:089590
|
$129.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinphar Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,098,338,000 to 3,263,201,000, a change of 164,863,000 (5.3%).
- Net income of 304,705,000 contributed positively to equity growth.
- Dividend payments of 167,722,000 reduced retained earnings.
- Other comprehensive income decreased equity by 318,426,000.
- Other factors increased equity by 346,306,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$304.70 Million | +9.34% |
| Dividends Paid | NT$167.72 Million | -5.14% |
| Other Comprehensive Income | NT$-318.43 Million | -9.76% |
| Other Changes | NT$346.31 Million | +10.61% |
| Total Change | NT$- | 5.32% |
Book Value vs Market Value Analysis
This analysis compares Sinphar Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.77x to 1.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | NT$8.27 | NT$31.20 | x |
| 2005-12-31 | NT$10.44 | NT$31.20 | x |
| 2006-12-31 | NT$10.43 | NT$31.20 | x |
| 2007-12-31 | NT$10.68 | NT$31.20 | x |
| 2008-12-31 | NT$11.16 | NT$31.20 | x |
| 2009-12-31 | NT$13.45 | NT$31.20 | x |
| 2010-12-31 | NT$13.85 | NT$31.20 | x |
| 2011-12-31 | NT$16.60 | NT$31.20 | x |
| 2012-12-31 | NT$15.08 | NT$31.20 | x |
| 2013-12-31 | NT$17.94 | NT$31.20 | x |
| 2014-12-31 | NT$19.70 | NT$31.20 | x |
| 2015-12-31 | NT$17.77 | NT$31.20 | x |
| 2016-12-31 | NT$18.43 | NT$31.20 | x |
| 2017-12-31 | NT$18.32 | NT$31.20 | x |
| 2018-12-31 | NT$17.44 | NT$31.20 | x |
| 2019-12-31 | NT$15.35 | NT$31.20 | x |
| 2020-12-31 | NT$15.15 | NT$31.20 | x |
| 2021-12-31 | NT$15.03 | NT$31.20 | x |
| 2022-12-31 | NT$16.15 | NT$31.20 | x |
| 2023-12-31 | NT$17.10 | NT$31.20 | x |
| 2024-12-31 | NT$17.98 | NT$31.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinphar Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.34%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.67%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.93x
- Recent ROE (9.34%) is above the historical average (4.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 7.09% | 6.77% | 0.55x | 1.89x | NT$-25.47 Million |
| 2003 | 7.52% | 6.38% | 0.54x | 2.19x | NT$-23.38 Million |
| 2004 | 10.24% | 8.65% | 0.60x | 1.97x | NT$2.85 Million |
| 2005 | 10.33% | 9.06% | 0.60x | 1.89x | NT$4.96 Million |
| 2006 | 2.92% | 2.68% | 0.59x | 1.85x | NT$-106.39 Million |
| 2007 | 5.24% | 4.57% | 0.56x | 2.06x | NT$-73.25 Million |
| 2008 | 2.87% | 2.55% | 0.50x | 2.23x | NT$-114.63 Million |
| 2009 | 6.72% | 7.23% | 0.51x | 1.84x | NT$-63.97 Million |
| 2010 | 5.47% | 6.09% | 0.49x | 1.83x | NT$-91.74 Million |
| 2011 | 2.92% | 3.92% | 0.40x | 1.87x | NT$-175.28 Million |
| 2012 | 4.92% | 5.96% | 0.46x | 1.79x | NT$-128.62 Million |
| 2013 | 10.00% | 11.66% | 0.45x | 1.90x | NT$-125.40K |
| 2014 | 4.94% | 6.18% | 0.41x | 1.96x | NT$-167.03 Million |
| 2015 | 0.43% | 0.64% | 0.34x | 1.98x | NT$-307.94 Million |
| 2016 | 0.54% | 0.78% | 0.34x | 2.01x | NT$-292.63 Million |
| 2017 | 1.19% | 1.72% | 0.35x | 1.97x | NT$-270.76 Million |
| 2018 | 0.30% | 0.40% | 0.38x | 2.01x | NT$-283.82 Million |
| 2019 | 0.50% | 0.58% | 0.40x | 2.13x | NT$-264.35 Million |
| 2020 | -1.04% | -1.19% | 0.39x | 2.23x | NT$-302.95 Million |
| 2021 | -1.40% | -1.57% | 0.39x | 2.29x | NT$-310.36 Million |
| 2022 | 7.67% | 7.86% | 0.46x | 2.11x | NT$-68.38 Million |
| 2023 | 12.11% | 12.66% | 0.47x | 2.02x | NT$65.34 Million |
| 2024 | 9.34% | 9.67% | 0.50x | 1.93x | NT$-21.62 Million |
Industry Comparison
This section compares Sinphar Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $977,341,444
- Average return on equity (ROE) among peers: 8.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinphar Pharmaceutical Co Ltd (1734) | NT$3.57 Billion | 7.09% | 0.71x | $129.70 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |